Key Takeaways & Executive Findings
- •• UHPLC-QTOF-MS identified 45 major bioactive compounds in the TCM formulation, including flavonoids, saponins, and alkaloids. • Network pharmacology revealed 120 potential protein targets involved in inflammation, apoptosis, and oxidative stress pathways. • In vitro assays confirmed significant anti-inflammatory and antioxidant activities, with IC50 values ranging from 10 to 50 μg/mL. • Molecular docking demonstrated strong binding affinities between key compounds and target proteins such as TNF-α and COX-2, supporting the formulation's therapeutic potential.
Abstract
Traditional Chinese Medicine (TCM) formulations have been used for centuries to treat various diseases. However, their chemical complexity and multi-target mechanisms remain poorly understood. This study characterizes the chemical composition and pharmacological properties of a representative TCM formulation using advanced analytical techniques and network pharmacology. Ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS) identified 45 major compounds, including flavonoids, saponins, and alkaloids. Network pharmacology analysis revealed that these compounds target 120 proteins involved in inflammation, apoptosis, and oxidative stress pathways. In vitro assays demonstrated significant anti-inflammatory and antioxidant activities, with IC50 values ranging from 10 to 50 μg/mL. Molecular docking studies indicated strong binding affinities between key compounds and target proteins, such as TNF-α and COX-2. These findings provide a scientific basis for the therapeutic use of TCM formulations and highlight their potential as sources of novel drug leads.
1. Introduction
Traditional Chinese Medicine (TCM) has been practiced for thousands of years and remains an integral part of healthcare in many Asian countries. TCM formulations, which combine multiple herbs, are believed to exert synergistic effects through multi-target mechanisms. However, the complex chemical composition and pharmacological basis of these formulations are not fully understood, hindering their modernization and global acceptance.
Recent advances in analytical chemistry and bioinformatics have enabled comprehensive characterization of TCM formulations. Techniques such as ultra-high-performance liquid chromatography coupled with mass spectrometry (UHPLC-MS) allow for the identification of numerous compounds, while network pharmacology provides a systems-level understanding of their interactions with biological targets. This study aims to characterize the chemical composition and pharmacological properties of a representative TCM formulation, integrating experimental and computational approaches to elucidate its mechanisms of action.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, J. Chen (2026). Characterization of Chemical Composition and Pharmacological Properties of Traditional Chinese Medicine Formulations. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main focus of this study?
This study characterizes the chemical composition and pharmacological properties of a traditional Chinese medicine formulation using advanced analytical techniques and network pharmacology.
How many compounds were identified in the TCM formulation?
A total of 45 major compounds were identified, including flavonoids, saponins, and alkaloids.
What are the key pharmacological activities of the formulation?
The formulation exhibited significant anti-inflammatory and antioxidant activities, with IC50 values ranging from 10 to 50 μg/mL.
What methods were used in this study?
The study employed UHPLC-QTOF-MS for chemical profiling, network pharmacology for target prediction, in vitro assays for activity evaluation, and molecular docking for binding affinity analysis.
What is the significance of this research?
The findings provide a scientific basis for the therapeutic use of TCM formulations and highlight their potential as sources of novel drug leads.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.